Navigation Links
Impact of Canada's Common Drug Review on drug listing
Date:10/24/2011

The number of drugs covered by public drug plans decreased substantially after Canada's Common Drug Review was introduced in 2003, and new drugs were listed more quickly in several of the smaller provinces, found a study published in CMAJ (Canadian Medical Association Journal) (pre-embargo link only) http://www.cmaj.ca/site/embargo/cmaj110670.pdf.

Canada has 19 public drug plans, which accounted for about 39% of the forecasted $31 billion in drug-related costs in 2010. These plans cover the cost of a range of drugs prescribed to patients. Before 2003, each plan independently reviewed evidence for clinical and cost-effectiveness for new drugs under consideration for listing under drug plans. The Canada Common Drug Review, administered by the Canadian Agency for Drugs and Technologies in Health, was introduced to standardize the process, improve efficiencies by pooling resources and expertise and eliminate duplication. Quebec does not participate in the Common Drug Review.

Researchers from the University of Alberta found that the number of drugs listed for coverage decreased substantially. Participating drug plans listed between 47% and 66% of new drugs in the five years before the Common Drug Review and between 12% and 40% in the five years following. As well, the time from recommendation to be listed and actual date listed ranged from 99 to 358 days, compared with an average time-to-listing of 778 days more than two years before the Common Drug Review.

There was also significant variation between listing decisions of public drug plans and recommendations of the Common Drug Review.

"The proportion of drugs listed decreased significantly after the introduction of the Common Drug Review for all participating drug plans included in our analysis," states Dr. Dean Eurich, School of Public Health, University of Alberta, with coauthors. "Time-to-listing decreased for a number of the smaller provinces."

The authors write that several factors, including uncertainty over the clinical effectiveness of drugs submitted by pharmaceutical companies for review, may explain the decrease in the number of drugs listed for reimbursement.

"Our findings suggest that the Common Drug Review may have contributed to a streamlining of the process for reviewing drugs for certain jurisdictions," write the authors "Specifically, patients in the provinces of New Brunswick, Prince Edward Island, and Newfoundland and Labrador may have benefited with earlier access to new drugs. Any substantial gains in savings or in the efficiency of publicly funded drug plans to make listing decisions are important factors in maintaining the health and safety of Canadian patients."


'/>"/>

Contact: Kim Barnhardt
kim.barnhardt@cmaj.ca
613-520-7116 x2224
Canadian Medical Association Journal
Source:Eurekalert

Related medicine news :

1. Experts weigh the heavy impact words have when creating policies for better health
2. National survey will measure how bullying impacts children with autism
3. Heart health impacts wellbeing of patients with chronic obstructive pulmonary disease
4. Circadian clock may impact organ transplant success
5. Study sheds light on the impact of COPD on working aged populations
6. Health Impact Project director comments on new National Research Council report
7. Sex hormones impact career choices
8. Double damage: Partner violence impacts mental health of over half-million Californians
9. Patients are living longer with ICDs, but pacing impacts survival rates
10. UCSF study shows greater impact of chemotherapy on fertility
11. Study: Community organization can reduce, negate impact of alcohol outlets on neighborhood violence
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... ... ... Lori G. Cohen and Sara K. Thompson , shareholders ... American Conference Institute’s 21st Drug & Medical Device Litigation Conference , taking place in ... , Cohen, who chairs the firm’s Pharmaceutical, Medical Device & Health Care Litigation Practice ...
(Date:12/2/2016)... ... ... over twenty-four years, Doctors on Liens has published a directory of the top ... care. When the company started in 1997, the directory was a single page focusing ... now ten-page directory features a vast array of medical specialists stretching from Sacramento ...
(Date:12/2/2016)... California (PRWEB) , ... December 02, 2016 , ... ... professionals, proudly announces the launch of its 60-day free trial program for all ... trip shipping make the offer a truly hassle free experience. , FlexiSpot’s unique ...
(Date:12/2/2016)... (PRWEB) , ... December 02, 2016 , ... U.S. Surgeon ... interview with Mediaplanet, Dr. Murthy explains how he was inspired to practice medicine at ... learned that medicine is about more than making diagnoses and prescribing medicine,” he states. ...
(Date:12/2/2016)... ... December 02, 2016 , ... ... Hills, California, will be included in the 2016 “Guide to America’s Top Plastic ... based on the amalgamation of their education, experience, and professional associations. , ...
Breaking Medicine News(10 mins):
(Date:12/2/2016)... December 2, 2016 On Thursday, the ... the Dow Jones Industrial Average edged 0.36% higher, to finish ... 0.35%. Losses were broad based as six out of nine ... research reports on the following Services equities: Myriad Genetics Inc. ... QGEN ), INC Research Holdings Inc. (NASDAQ: INCR ...
(Date:12/2/2016)... 2016 The concept of rare diseases and the ... this sector has been taking shape in Europe ... aspects and initiatives related to orphan medicinal products have been ... of member states individually. Many member states in the EU ... of orphan medicinal products, the result of which took the ...
(Date:12/2/2016)... 1, 2016 Around the corners of world, ... each habitable land present over earth. Cancer has become ... in a life time this is because of the ... now. Given the steady increase in global cancer incidence ... spiraling healthcare costs of treatment, there is increasing interest ...
Breaking Medicine Technology: